Nuclear Medicine
The division of nuclear radiology and molecular imaging at the University of Nebraska Medical Center is a leader in providing advanced diagnostic imaging services and therapeutic treatments that are not widely available elsewhere for both adult and pediatric patients. We provide radionuclide diagnostic imaging studies in general nuclear medicine, PET/CT, SPECT/CT, administer radionuclide therapy/theranostics, and perform nuclear cardiology services.

Nuclear radiology can be helpful in providing physicians with both diagnostic and functional physiologic information of the patient’s cells, tissues, or organs. Our expertise and specialized equipment make us a preferred referral center for many specialty physicians throughout Nebraska and surrounding states.

General nuclear medicine studies including a wide variety of both planar and SPECT/CT imaging such as HIDA scans, bone scans, renal and GFR studies,  gastric emptying studies, thyroid and parathyroid imaging, lung ventilation/perfusions scans, MIBG studies, seizure imaging, brain death imaging, plasma volume, and pre-surgical lymph node scintigraphy.

We provide PET/CT diagnostic imaging of patients with suspected or known illnesses such as malignancy, infection, dementia, intractable seizures, or other disorders requiring anatomic problem-solving. PET/CT radiotracer agents that are available include F-18 FDG for metabolic imaging, F-18 fluciclovine for prostate cancer imaging, and Ga-68 DOTATATE for imaging of neuroendocrine tumors.

The division provides nuclear cardiology services including rest/stress myocardial perfusion imaging, MUGA studies, cardiac amyloidosis scans, and PET/CT myocardial viability and cardiac sarcoidosis imaging.

We also provide a therapeutic nuclear radiology and theranostics service including Iodine-131 therapy for treatment of thyroid cancer and hyperthyroidism, Xofigo (Ra-223) therapy for bone metastases in prostate cancer, Y-90 microsphere therapy with interventional radiology for primary and secondary hepatic malignances, and Lutathera (Lu-177 DOTATATE) therapy for neuroendocrine tumors.